Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This early-phase study is testing a new formulation of a drug called fenretinide (delivered as tiny particles called nanoparticles) in patients with relapsed or treatment-resistant T-cell lymphomas — a group of blood cancers involving T-cells of the immune system. **You may be eligible if...** - You have a confirmed diagnosis of a T-cell lymphoma (including cutaneous T-cell lymphoma such as mycosis fungoides, Sézary syndrome, or peripheral T-cell lymphoma) - Your lymphoma has come back or stopped responding to at least one prior treatment - You have at least one measurable site of disease - You are in reasonably good health and your organ function meets study requirements **You may NOT be eligible if...** - You have not received any prior treatment for your lymphoma - Your cancer is a different type of lymphoma not listed in the study - You have serious uncontrolled health conditions - You are pregnant or breastfeeding - You have significant organ dysfunction Talk to your doctor to see if this trial is right for you.